Table 1 Characteristics of 3910 individuals initiating HAART at Themba Lethu Clinical by baseline dose of stavudine
| Baseline characteristic | Dose of stavudine | |
|---|---|---|
|
40 mg
n = 2445 |
30 mg
n = 1465 | |
| Weight† | 67.0 (62.8-74.0) | 68.1 (63.6-75.6) |
| Age† | 37 (32-43) | 38 (33-44) |
| Male gender | 1017(41.6) | 628 (42.9) |
| African ethnicity | 2,348 (96.0) | 1,416 (96.7) |
| Employed | 1,130 (46.2) | 855 (58.4) |
| Tuberculosis | 364 (14.9) | 155 (10.6) |
| Haemoglobin (low) | 823 (35.0) | 433 (29.8) |
| WHO stage III or IV | 956 (39.1) | 356 (24.3) |
| CD4 count (cells/mm3)† | 97 (39-163) | 137 (66-192) |
| Efavirenz-based HAART | 2203 (90.1) | 1296 (88.5) |
| Nevirapine-based HAART | 193 (7.9) | 116 (7.9) |